Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 10, 2026
- Co-Diagnostics reported third-quarter revenue of $0.3 million versus $0.1 million in the third quarter of 2025, but net loss was $6.3 million versus $5.9 million. Cash and cash equivalents totaled $0.7 million as of September 30, 2026.
- 10-Q report · filed Nov 10, 2026
- Co-Diagnostics reported $0.7 million cash and cash equivalents at September 30, 2026, versus total current liabilities of $2.5 million, and said additional capital is required, creating substantial doubt about its ability to continue as a going concern.
The audio replay and transcript follow the call.